Sangamo Free Cash Flow Yield vs Free Cash Flow Analysis

SGMO Stock  USD 1.22  0.15  10.95%   
Sangamo Therapeutics financial indicator trend analysis is much more than just breaking down Sangamo Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sangamo Therapeutics is a good investment. Please check the relationship between Sangamo Therapeutics Free Cash Flow Yield and its Free Cash Flow accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.

Free Cash Flow Yield vs Free Cash Flow

JavaScript chart by amCharts 3.21.1520162018202020222024-3.0-2.8-2.6-2.4-2.2-2.0-1.8-1.6-1.4-1.2-1.0-0.8-0.6-0.4-0.20 -250M-200M-150M-100M-50M050M100M150M
JavaScript chart by amCharts 3.21.15Free Cash Flow Yieldtotal: -9.629166678371291Free Cash Flowtotal: -1.3B

Free Cash Flow Yield vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sangamo Therapeutics Free Cash Flow Yield account and Free Cash Flow. At this time, the significance of the direction appears to have strong relationship.
Free Cash Flow YieldFree Cash FlowDiversified AwayFree Cash Flow YieldFree Cash FlowDiversified Away100%
The correlation between Sangamo Therapeutics' Free Cash Flow Yield and Free Cash Flow is 0.65. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of Sangamo Therapeutics, assuming nothing else is changed. The correlation between historical values of Sangamo Therapeutics' Free Cash Flow Yield and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Sangamo Therapeutics are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Free Cash Flow Yield i.e., Sangamo Therapeutics' Free Cash Flow Yield and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

0.65
Relationship DirectionPositive 
Relationship StrengthSignificant

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
Most indicators from Sangamo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sangamo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.As of the 9th of January 2025, Selling General Administrative is likely to grow to about 73.9 M, though Tax Provision is likely to grow to (5 M).
 2022 2023 2024 2025 (projected)
Reconciled Depreciation20.6M24.6M28.3M29.7M
Net Interest Income9.4M13.3M15.3M7.9M

Sangamo Therapeutics fundamental ratios Correlations

0.97-0.340.890.380.480.970.720.750.940.870.320.880.940.190.970.430.030.890.970.670.970.02-0.780.670.45
0.97-0.230.820.280.380.890.620.650.840.780.20.820.870.060.960.55-0.10.920.890.550.97-0.12-0.750.520.35
-0.34-0.23-0.33-0.97-0.97-0.44-0.83-0.45-0.56-0.67-0.89-0.43-0.48-0.94-0.20.04-0.19-0.04-0.39-0.87-0.24-0.230.11-0.71-0.86
0.890.82-0.330.310.410.910.70.580.910.880.380.820.940.160.790.330.190.70.90.70.80.17-0.730.810.39
0.380.28-0.970.310.990.450.820.50.550.680.890.440.480.950.270.00.130.10.420.870.30.17-0.120.680.87
0.480.38-0.970.410.990.550.870.550.640.760.880.530.570.930.360.060.150.190.510.910.390.19-0.20.730.89
0.970.89-0.440.910.450.550.780.810.980.910.430.890.950.310.910.260.170.810.990.750.910.16-0.770.790.53
0.720.62-0.830.70.820.870.780.620.850.930.710.730.810.740.580.30.260.440.750.950.610.28-0.430.790.82
0.750.65-0.450.580.50.550.810.620.780.660.480.590.640.410.760.030.190.750.820.590.780.19-0.440.60.48
0.940.84-0.560.910.550.640.980.850.780.930.530.90.950.420.860.210.180.740.960.820.860.18-0.740.850.62
0.870.78-0.670.880.680.760.910.930.660.930.640.850.950.560.730.350.260.590.890.940.760.27-0.620.860.73
0.320.2-0.890.380.890.880.430.710.480.530.640.320.480.860.17-0.080.260.040.390.830.20.29-0.040.780.73
0.880.82-0.430.820.440.530.890.730.590.90.850.320.880.310.820.170.070.660.880.710.830.07-0.930.710.59
0.940.87-0.480.940.480.570.950.810.640.950.950.480.880.330.830.40.180.70.940.810.830.17-0.730.820.55
0.190.06-0.940.160.950.930.310.740.410.420.560.860.310.330.07-0.180.33-0.10.280.80.10.380.010.610.88
0.970.96-0.20.790.270.360.910.580.760.860.730.170.820.830.070.38-0.070.950.930.510.99-0.09-0.780.530.33
0.430.550.040.330.00.060.260.30.030.210.35-0.080.170.4-0.180.38-0.120.430.280.180.41-0.14-0.08-0.04-0.07
0.03-0.1-0.190.190.130.150.170.260.190.180.260.260.070.180.33-0.07-0.12-0.130.160.33-0.061.00.010.320.28
0.890.92-0.040.70.10.190.810.440.750.740.590.040.660.7-0.10.950.43-0.130.830.330.96-0.15-0.640.360.16
0.970.89-0.390.90.420.510.990.750.820.960.890.390.880.940.280.930.280.160.830.720.930.15-0.770.750.5
0.670.55-0.870.70.870.910.750.950.590.820.940.830.710.810.80.510.180.330.330.720.540.35-0.420.880.86
0.970.97-0.240.80.30.390.910.610.780.860.760.20.830.830.10.990.41-0.060.960.930.54-0.07-0.760.530.37
0.02-0.12-0.230.170.170.190.160.280.190.180.270.290.070.170.38-0.09-0.141.0-0.150.150.35-0.070.030.330.31
-0.78-0.750.11-0.73-0.12-0.2-0.77-0.43-0.44-0.74-0.62-0.04-0.93-0.730.01-0.78-0.080.01-0.64-0.77-0.42-0.760.03-0.52-0.32
0.670.52-0.710.810.680.730.790.790.60.850.860.780.710.820.610.53-0.040.320.360.750.880.530.33-0.520.64
0.450.35-0.860.390.870.890.530.820.480.620.730.730.590.550.880.33-0.070.280.160.50.860.370.31-0.320.64
Click cells to compare fundamentals

Sangamo Therapeutics Account Relationship Matchups

Sangamo Therapeutics fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets938.6M721.9M562.5M165.3M190.1M218.1M
Total Stockholder Equity497.4M375.3M295.0M82.9M95.3M144.6M
Retained Earnings(778.0M)(956.3M)(1.1B)(1.4B)(1.3B)(1.2B)
Other Assets15.1M16.8M18.5M1.01.151.09
Common Stock Shares Outstanding134.4M144.6M154.3M174.4M200.6M210.6M
Liabilities And Stockholders Equity938.6M721.9M562.5M165.3M190.1M218.1M
Other Stockholder Equity1.3B1.3B1.5B1.5B1.7B1.8B
Total Liab441.2M346.6M267.6M82.4M94.8M73.5M
Short Long Term Debt Total42.1M48.1M43.1M38.1M43.8M30.0M
Other Current Liab127.3M28.4M33.4M27.9M32.1M33.7M
Total Current Liabilities143.5M127.9M111.7M47.7M54.9M34.0M
Property Plant And Equipment Net112.4M124.7M125.5M52.9M60.8M63.8M
Accounts Payable12.6M9.8M22.4M15.3M17.5M18.4M
Cash131.3M178.9M100.4M45.2M52.0M45.0M
Non Current Assets Total278.9M323.2M262.2M71.0M81.6M68.1M
Non Currrent Assets Other7.9M10.2M12.3M18.1M20.8M21.9M
Cash And Short Term Investments692.0M464.7M277.6M81.0M93.2M179.1M
Net Receivables6.3M6.4M4.5M1.3M1.5M1.4M
Common Stock Total Equity1.2M1.4M1.5M1.7M1.5M1.4M
Short Term Investments510.1M197.7M177.2M35.8M41.2M39.1M
Non Current Liabilities Total297.6M218.7M155.8M34.7M39.9M57.7M
Property Plant And Equipment Gross112.4M149.7M162.1M103.9M119.5M125.5M
Total Current Assets659.7M398.8M300.3M94.3M108.5M175.7M
Accumulated Other Comprehensive Income5.4M(4.0M)(8.4M)(4.6M)(4.1M)(3.9M)
Common Stock1.4M1.5M1.7M1.8M1.6M1.5M
Net Debt(89.2M)(130.8M)(57.3M)(7.1M)(6.4M)(6.7M)
Other Current Assets24.0M31.7M36.4M12M13.8M14.5M
Property Plant Equipment29.9M41.3M51.5M63.5M73.1M76.7M
Current Deferred Revenue38.7M96.6M85.7M51.8M59.5M62.5M
Short Term Debt3.7M4.0M4.1M4.6M5.3M3.5M
Intangible Assets53.2M58.1M53.8M50.7M58.3M61.3M
Other Liab93.7M259.2M174.6M116.9M134.4M141.1M
Net Tangible Assets340.1M397.3M281.9M206.7M237.7M227.0M
Retained Earnings Total Equity(657.0M)(778.0M)(956.3M)(1.1B)(1.0B)(982.0M)
Capital Surpluse1.1B1.3B1.3B1.5B1.7B873.1M
Inventory(22.5M)(50.5M)(88.2M)1.00.90.95
Deferred Long Term Liab6.6M7.2M6.6M6.3M7.2M9.3M

Pair Trading with Sangamo Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sangamo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangamo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Sangamo Stock

  0.7MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.65PFE Pfizer Inc Aggressive PushPairCorr
  0.61LLY Eli LillyPairCorr
  0.45JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.43UPC Universe PharmaceuticalsPairCorr
The ability to find closely correlated positions to Sangamo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sangamo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sangamo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sangamo Therapeutics to buy it.
The correlation of Sangamo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sangamo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sangamo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sangamo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.24)
Revenue Per Share
0.066
Quarterly Revenue Growth
(0.95)
Return On Assets
(0.58)
Return On Equity
(1.94)
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
News Freq…Investor S…